NMTC vs. PDEX, LNSR, LAKE, AVR, PROF, ZJYL, LUCD, RCEL, OBIO, and INO
Should you be buying NeuroOne Medical Technologies stock or one of its competitors? The main competitors of NeuroOne Medical Technologies include Pro-Dex (PDEX), LENSAR (LNSR), Lakeland Industries (LAKE), Anteris Technologies Global (AVR), Profound Medical (PROF), Jin Medical International (ZJYL), Lucid Diagnostics (LUCD), Avita Medical (RCEL), Orchestra BioMed (OBIO), and Inovio Pharmaceuticals (INO). These companies are all part of the "medical equipment" industry.
NeuroOne Medical Technologies vs. Its Competitors
Pro-Dex (NASDAQ:PDEX) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.
In the previous week, Pro-Dex had 1 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 2 mentions for Pro-Dex and 1 mentions for NeuroOne Medical Technologies. Pro-Dex's average media sentiment score of 0.34 beat NeuroOne Medical Technologies' score of -1.00 indicating that Pro-Dex is being referred to more favorably in the media.
Pro-Dex has a net margin of 14.61% compared to NeuroOne Medical Technologies' net margin of -55.44%. Pro-Dex's return on equity of 29.08% beat NeuroOne Medical Technologies' return on equity.
Pro-Dex has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.
15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 47.5% of Pro-Dex shares are owned by insiders. Comparatively, 8.9% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Pro-Dex has higher revenue and earnings than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.
Pro-Dex currently has a consensus target price of $56.00, indicating a potential upside of 20.51%. NeuroOne Medical Technologies has a consensus target price of $1.45, indicating a potential upside of 94.94%. Given NeuroOne Medical Technologies' higher probable upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Pro-Dex.
Summary
Pro-Dex beats NeuroOne Medical Technologies on 10 of the 14 factors compared between the two stocks.
Get NeuroOne Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroOne Medical Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:NMTC) was last updated on 9/4/2025 by MarketBeat.com Staff
Free NMTC Stock Alerts